---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230409"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:46:29.522706+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ovid reports positive Phase 1 OV329 results and raises $175M in PIPE financing

## Summary
- OV329 Phase 1: 53% inhibition increase on LICI biomarker (p=0.0001) at 5mg, exceeding vigabatrin (~35%); mild AEs only.
- No ophthalmic changes observed; plan Phase 2a in drug-resistant focal onset seizures Q2 2026.
- PIPE financing of up to $175.1M (initial $80.8M) from sale of Series B Preferred and warrants at $1.40/share.
- Warrants exercisable after stockholder approval; proceeds for R&D and working capital; closing Oct 6, 2025.
- KCC2 program updates: OV350 topline PK data Q4 2025; OV4071 IND filing Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-230409
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/d45212d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230409
- JSON: https://secwatch.observer/filing/0001193125-25-230409.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230409.txt

## Key facts
- Equity Issuances
  Ovid Therapeutics Inc. issued to purchase 38,481,325 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.
  - Security: warrant
  - Shares: to purchase 38,481,325 shares of Common Stock
  - Purchaser: the Investors (including the Chief Executive Officer)
  - Consideration: $1,400.00 per Security
  source text: purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm
- Equity Issuances
  Ovid Therapeutics Inc. issued 57,722 shares of preferred stock to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.
  - Security: preferred stock
  - Shares: 57,722 shares
  - Purchaser: the Investors (including the Chief Executive Officer)
  - Consideration: $1,400.00 per Security
  source text: purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm
- Equity Issuances
  Ovid Therapeutics Inc. issued to purchase 28,861,000 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.
  - Security: warrant
  - Shares: to purchase 28,861,000 shares of Common Stock
  - Purchaser: the Investors (including the Chief Executive Officer)
  - Consideration: $1,400.00 per Security
  source text: purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm
- Governance Changes
  Ovid Therapeutics Inc.: Filed Certificate of Designation establishing Series B Convertible Preferred Stock designating 57,722 shares of preferred stock (effective 2025-10-03).
  - Change: charter amendment
  - Effective: 2025-10-03
  source text: On October 3, 2025, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 57,722 shares of its authorized and unissued preferred stock as Series B Preferred Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000119312525230409/0001193125-25-230409-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.